ImClone Systems, LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.3M
Doctors Paid
15
Transactions
117
2024 Total
$476,400
Payment Breakdown by Category
Research$1.5M (46.4%)
Travel$399.07 (0.0%)
Food & Beverage$110.65 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.8M | 62 | 53.5% |
| Unspecified | $1.5M | 49 | 46.4% |
| Travel and Lodging | $399.07 | 3 | 0.0% |
| Food and Beverage | $110.65 | 3 | 0.0% |
Payments by Type
General
$1.8M
68 transactions
Research
$1.5M
49 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| PHASE 1 STUDY OF IMC-CS4 A MONOCLONAL ANTIBODY TARGETED TO THE CSF-1 RECEPTOR -CSF-1R- IN SUBJECTS WITH ADVANCED SOLID TUMORS REFRACTORY TO STANDARD THERAPY OR FOR WHICH NO STANDARD THERAPY IS AVAILABLE | $608,745 | 3 | 12 |
| E7208 PHII CETUX VS CETUX + RAMUCIRUMAB - COLON MED-P1-10001 | $287,368 | 0 | 1 |
| A PHASE III TRIAL OF IRINOTECAN 5-FU LEUCOVORIN OR OXALIPLATIN 5-FU LEUCOVORIN WITH BEVACIZUMAB OR CETUXIMAB C225 OR WITH THE COMBINATION OF BEVACIZUMAB AND CETUXIMAB FOR PATIENTS WITH UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM | $171,251 | 0 | 1 |
| A RANDOMIZED PHASE 2 STUDY OF HUMAN ANTI PDGFRA MONOCLONAL ANTIBODY -IMC-3G3- WITH PACLITAXEL CARBOPLATIN OR PACLITAXEL CARBOPLATIN ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER | $122,586 | 0 | 6 |
| A PHASE 1B-2 RANDOMIZED PHASE 2 STUDY EVALUATING THE EFFICACY OF DOXORUBICIN WITH OR WITHOUT A HUMAN ANTI PDGFRA MONOCLONAL ANTIBODY -IMC-3G3- IN THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA | $115,403 | 0 | 4 |
| A STUDY TO EVALUATE THE POTENTIAL OF CONCOMITANT RAMUCIRUMAB TO AFFECT THE PHARMACOKINETICS OF PACLITAXEL IN PATIENTS WITH ADVANCED MALIGNANT SOLID TUMORS | $59,156 | 0 | 6 |
| A MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF IMC-1121B PLUS DOCETAXEL VERSUS PLACEBO PLUS DOCETAXEL IN PREVIOUSLY UNTREATED PATIENTS WITH HER2-NEGATIVE, UNRESECTABLE, LOCALLY-RECURRENT OR METASTATIC BREAST CANCER | $45,650 | 0 | 2 |
| A STUDY TO EVALUATE THE POTENTIAL OF CONCOMITANT RAMUCIRUMAB TO AFFECT THE PHARMACOKINETICS OF IRINOTECAN AND ITS METABOLITE SN-38 WHEN COADMINISTERED WITH FOLINIC ACID AND 5 FLUOROURACIL IN PATIENTS WITH ADVANCED MALIGNANT SOLID TUMORS | $21,600 | 0 | 2 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF RAMUCIRUMAB -IMC-1121B- DRUG PRODUCT AND BEST SUPPORTIVE CARE -BSC- VERSUS PLACEBO AND BSC AS SECOND-LINE TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA FOLLOWING FIRST-LINE THERAPY WITH SORAF | $18,526 | 0 | 1 |
| AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF RAMUCIRUMAB -IMC-1121B- DRUG PRODUCT OR IMC-18F1 IN COMBINATION WITH CAPECITABINE OR CAPECITABINE MONOTHERAPY, IN UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC BREAS | $7,571 | 0 | 2 |
| AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF 5 FU-FA AND OXALIPLATIN -MODIFIED FOLFOX 6- IN COMBINATION WITH IMC-1121B OR IMC-18F1 OR WITHOUT INVESTIGATIONAL THERAPY AS SECOND LINE THERAPY IN PATIENTS WITH MET | $7,214 | 0 | 1 |
| AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF DOCETAXEL IN COMBINATION WITH RAMUCIRUMAB IMC-1121B DRUG PRODUCT OR IMC-18F1 OR WITHOUT INVESTIGATIONAL THERAPY AS SECOND-LINE THERAPY IN PATIENTS WITH LOCALLY ADVA | $6,750 | 0 | 1 |
| A RANDOMIZED PHASE 2 OPEN-LABEL STUDY OF IMC-A12, AS A SINGLE AGENT OR IN COMBINATION WITH CETUXIMAB, IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AND DISEASE PROGRESSION ON PRIOR PLATINUM-BASED CHEMOTHERAPY | $5,560 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Medical Oncology | $260,545 | 4 | $65,136 |
| Internal Medicine | $12,696 | 7 | $1,814 |
| Hematology & Oncology | $5,846 | 3 | $1,949 |
| Radiation Oncology | $1,700 | 1 | $1,700 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Robert Wesolowski, Md, MD | Medical Oncology | Columbus, OH | $255,696 | $0 |
| Dr. Gulam Manji, M.d./Ph.d, M.D./PH.D | Internal Medicine | New York, NY | $8,435 | $0 |
| Omid Hamid, M.d, M.D | Hematology & Oncology | Santa Monica, CA | $3,896 | $0 |
| David Scheinberg, Md, MD | Medical Oncology | New York, NY | $2,800 | $0 |
| Dr. Ross Levine, Md, MD | Internal Medicine | New York, NY | $2,200 | $0 |
| David Solit, Md, MD | Medical Oncology | New York, NY | $1,836 | $0 |
| Dr. Timothy Chan, Md, Phd, MD, PHD | Radiation Oncology | New York, NY | $1,700 | $0 |
| Daruka Mahadevan, Md, Phd, MD, PHD | Hematology & Oncology | San Antonio, TX | $1,100 | $0 |
| Patricia Lorusso, Do, DO | Internal Medicine | Detroit, MI | $1,100 | $0 |
| Dr. Alan Saven, M.d, M.D | Hematology & Oncology | La Jolla, CA | $850.00 | $0 |
| Moshe Talpaz, Md, MD | Internal Medicine | Ann Arbor, MI | $850.00 | $0 |
| Manish Shah, Md, MD | Medical Oncology | New York, NY | $213.49 | $0 |
| Alberto Chiappori, Md, MD | Internal Medicine | Tampa, FL | $61.12 | $0 |
| Dr. Melina Marmarelis, M.d, M.D | Internal Medicine | Philadelphia, PA | $24.77 | $0 |
| Corey Langer, Md, MD | Internal Medicine | Philadelphia, PA | $24.76 | $0 |
Ad
Top Products
- CYRAMZA $144,993
Payment Categories
- Food & Beverage $110.65
- Travel & Lodging $399.07
- Research $1.5M
About ImClone Systems, LLC
ImClone Systems, LLC has made $3.3M in payments to 15 healthcare providers, recorded across 117 transactions in the CMS Open Payments database. In 2024, the company paid $476,400. The top product by payment volume is CYRAMZA ($144,993).
Payments were distributed across 4 medical specialties. The top specialty by payment amount is Medical Oncology ($260,545 to 4 doctors).
Payment categories include: Food & Beverage ($110.65), Research ($1.5M), Travel & Lodging ($399.07).